T2 Biosystems, Inc. (TTOO): Price and Financial Metrics
TTOO Price/Volume Stats
Current price | $3.93 | 52-week high | $70.00 |
Prev. close | $4.18 | 52-week low | $3.36 |
Day low | $3.60 | Volume | 232,700 |
Day high | $4.33 | Avg. volume | 264,164 |
50-day MA | $4.87 | Dividend yield | N/A |
200-day MA | $12.74 | Market Cap | 15.92M |
TTOO Stock Price Chart Interactive Chart >
TTOO POWR Grades
- Growth is the dimension where TTOO ranks best; there it ranks ahead of 87.33% of US stocks.
- The strongest trend for TTOO is in Growth, which has been heading up over the past 140 days.
- TTOO's current lowest rank is in the Stability metric (where it is better than 0.85% of US stocks).
TTOO Stock Summary
- Revenue growth over the past 12 months for T2 BIOSYSTEMS INC comes in at -53.8%, a number that bests merely 4.29% of the US stocks we're tracking.
- In terms of volatility of its share price, TTOO is more volatile than 99.83% of stocks we're observing.
- T2 BIOSYSTEMS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -213.28%, greater than the shareholder yield of just 2.09% of stocks in our set.
- Stocks that are quantitatively similar to TTOO, based on their financial statements, market capitalization, and price volatility, are CHRS, RFL, AXTI, INTZ, and LAW.
- TTOO's SEC filings can be seen here. And to visit T2 BIOSYSTEMS INC's official web site, go to www.t2biosystems.com.
TTOO Valuation Summary
- In comparison to the median Healthcare stock, TTOO's price/sales ratio is 45.24% lower, now standing at 2.3.
- TTOO's price/sales ratio has moved down 1764.8 over the prior 114 months.
Below are key valuation metrics over time for TTOO.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
TTOO | 2023-12-29 | 2.3 | -1.3 | -0.5 | -1.1 |
TTOO | 2023-12-28 | 2.7 | -1.6 | -0.6 | -1.2 |
TTOO | 2023-12-27 | 1.9 | -1.1 | -0.4 | -1.0 |
TTOO | 2023-12-26 | 1.8 | -1.0 | -0.4 | -1.0 |
TTOO | 2023-12-22 | 1.9 | -1.1 | -0.4 | -1.0 |
TTOO | 2023-12-21 | 1.8 | -1.0 | -0.4 | -1.0 |
TTOO Growth Metrics
- Its 3 year net cashflow from operations growth rate is now at -8.1%.
- Its 5 year price growth rate is now at -85.29%.
- The 4 year net income to common stockholders growth rate now stands at -4.86%.
The table below shows TTOO's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 23.802 | -50.142 | -64.378 |
2022-06-30 | 27.553 | -43.966 | -60.635 |
2022-03-31 | 28.336 | -44.607 | -55.076 |
2021-12-31 | 28.058 | -38.874 | -49.241 |
2021-09-30 | 28.866 | -37.782 | -47.006 |
2021-06-30 | 26.683 | -34.289 | -44.299 |
TTOO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- TTOO has a Quality Grade of D, ranking ahead of 16.98% of graded US stocks.
- TTOO's asset turnover comes in at 0.387 -- ranking 118th of 186 Medical Equipment stocks.
- ICAD, STRR, and DRIO are the stocks whose asset turnover ratios are most correlated with TTOO.
The table below shows TTOO's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.387 | 0.210 | -0.411 |
2021-06-30 | 0.349 | 0.066 | -0.396 |
2021-03-31 | 0.321 | 0.006 | -0.405 |
2020-12-31 | 0.277 | -0.174 | -0.620 |
2020-09-30 | 0.254 | -0.298 | -1.132 |
2020-06-30 | 0.235 | -0.476 | -2.605 |
TTOO Price Target
For more insight on analysts targets of TTOO, see our TTOO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $2.20 | Average Broker Recommendation | 1.3 (Strong Buy) |
T2 Biosystems, Inc. (TTOO) Company Bio
T2 Biosystems develops diagnostic products and product candidates for the detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types. The company was founded in 2006 and is based in Lexington, Massachusetts.
Latest TTOO News From Around the Web
Below are the latest news stories about T2 BIOSYSTEMS INC that investors may wish to consider to help them evaluate TTOO as an investment opportunity.
Get Out Now! 7 Stocks That Are Destined to DieLooking to optimize your portfolio? |
T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumLEXINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NY. Management is scheduled to present on Thursday, November 16, 2023, at 8:00am ET. Interested parties may access a live and recorded webcast of the presentation |
TTOO Stock Alert: T2 Biosystems Regains Nasdaq ComplianceTTOO stock is back above $1 and is now officially in compliance with Nasdaq's minimum bid price requirement of $1. |
T2 Biosystems Regains Compliance with Nasdaq Listing RequirementsLEXINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that on October 31, 2023 it received written notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company regained compliance with the minimum bid price requirement (the “Minimum Bid Price Requirement”), as set forth in Nasdaq Lis |
T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 ConferenceData demonstrates speed, accuracy, and clinical benefits of the T2Dx Instrument and T2 Biosystems’ sepsis panels, including encouraging early detection data for T2Resistance PanelLEXINGTON, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted four new studies supporting the T2Bacteria® Panel, the T2Candida® Panel and the T2Resistance® Panel that were recently pres |
TTOO Price Returns
1-mo | -27.89% |
3-mo | -25.85% |
6-mo | -86.44% |
1-year | -91.90% |
3-year | -99.96% |
5-year | -99.97% |
YTD | -37.37% |
2023 | -95.58% |
2022 | -94.50% |
2021 | -58.37% |
2020 | 5.98% |
2019 | -61.13% |
Continue Researching TTOO
Want to see what other sources are saying about T2 Biosystems Inc's financials and stock price? Try the links below:T2 Biosystems Inc (TTOO) Stock Price | Nasdaq
T2 Biosystems Inc (TTOO) Stock Quote, History and News - Yahoo Finance
T2 Biosystems Inc (TTOO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...